Black Diamond Therapeutics (BDTX) AI Stock Analysis

• Market Cap: $158.96M
• Dividend Yield: N/A
• Average Volume (3M): 1.32M
• Price to Earnings (P/E): 7.7
• Beta (1Y): 2.10
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.15
• Shares Outstanding: 56,974,915
• 10 Day Avg. Volume: 923,456
• 30 Day Avg. Volume: 1,316,104
• PEG Ratio: 0.05
• Price to Book (P/B): 1.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.89
• Enterprise Value/Market Cap: 1.26
• Enterprise Value/Revenue: 2.87
• Enterprise Value/Gross Profit: 2.87
• Enterprise Value/Ebitda: 11.46
• 1Y Price Target: $9.00
• Price Target Upside: 222.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -0.63
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: $3.00 ▲(7.53% Upside)

The score is supported mainly by improved TTM fundamentals (profitability, positive free cash flow, low leverage) and a low P/E, plus a favorable Phase 2 clinical update. These positives are tempered by a weak technical backdrop (below key moving averages with negative MACD) and the higher uncertainty implied by BDTX’s prior multi-year history of losses and negative cash flows.

Positive Factors

Clinical Efficacy (silevertinib)

Robust preliminary ORR and CNS activity materially de-risks the lead program by demonstrating target engagement and intracranial benefit. Durable clinical signal increases the probability of later-line label expansion and partnerships, supporting long-term commercial potential if confirmed.

TTM Cash Generation

A sustained shift to positive operating and free cash flow improves financial flexibility and reduces near-term reliance on capital markets. If maintained, this supports funding R&D internally, lowers dilution risk, and enhances the company's ability to advance multiple clinical programs.

Cash Runway

A multi-year runway provides time to complete key randomized and registrational trials without immediate fundraising. This enables strategic execution of GBM and NSCLC programs, preserves negotiating leverage with partners, and reduces short-term financing pressure on the business model.

Negative Factors

Historic Losses & Volatility

The company’s recent TTM inflection follows years of zero revenue and large losses, implying earnings volatility. This history raises uncertainty that current profitability is structural rather than transient, increasing the risk of future capital needs if clinical or revenue trends regress.

Revenue Model Concentration

Dependence on upfront, milestone and financing income creates lumpy, binary revenue streams tied to trial outcomes and partner decisions. Without an approved product, predictable recurring sales are absent, leaving long-term cashflows contingent on successful development or repeated financing events.

Clinical Execution Risk

Positive Phase 2 signals still face confirmatory trial, regulatory and execution hurdles. The planned GBM randomized study is multi-year and binary; failure or delays would materially affect projected revenues, cash burn assumptions and the company’s ability to sustain programs without additional financing.

Black Diamond Therapeutics Business Overview & Revenue Model

Company Description

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Black Diamond Therapeutics makes money primarily through the development and commercialization of its pharmaceutical products targeting specific mutations in cancer treatment. The company generates revenue by advancing its proprietary drug candidates through clinical trials, seeking regulatory approval, and ultimately bringing these therapies to market. Significant revenue streams may include sales of approved drugs, partnerships, and collaborations with larger pharmaceutical companies for co-development and commercialization efforts. Additionally, the company may receive milestone payments and royalties from licensing agreements, providing a diversified approach to revenue generation. However, as a biotechnology company in the clinical development stage, Black Diamond Therapeutics may also rely on funding from investors and financial markets until its products are commercially available.

Black Diamond Therapeutics Financial Statement Overview

Summary

Black Diamond Therapeutics is facing significant financial challenges, characterized by zero revenue generation, negative equity, and persistent negative cash flows. The company may depend heavily on financing activities to sustain operations, which poses a high-risk profile typical for early-stage biotechnology firms.

Income Statement

The company has consistently reported zero revenue over the years, indicating a lack of commercialized products or services. This results in gross profit and net income being highly negative. The EBIT and EBITDA margins are unavailable due to zero revenue, and the overall income statement shows a persistent negative net income trend.

Balance Sheet

The balance sheet reveals a challenging financial position with negative stockholders' equity for multiple years, indicating financial instability. The debt-to-equity ratio is not applicable due to negative equity, and the company has high liabilities relative to its assets. The equity ratio is also negative, underscoring the precarious financial health.

Cash Flow

Operating cash flow is consistently negative, reflecting ongoing cash burn without revenue generation. While there is some positive movement in investing and financing cash flows, the free cash flow remains negative with no growth, suggesting a reliance on external funding to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	70.00M	0.00	0.00	0.00	0.00	0.00
Gross Profit	69.91M	0.00	-437.00K	0.00	0.00	-600.00K
EBITDA	17.54M	-78.44M	-86.02M	-92.32M	-126.67M	-66.65M
Net Income	21.50M	-69.68M	-82.44M	-91.17M	-125.60M	-67.25M
Balance Sheet
Total Assets	157.73M	122.64M	158.57M	156.25M	247.68M	329.67M
Cash, Cash Equivalents and Short-Term Investments	135.50M	98.58M	131.40M	122.81M	209.79M	315.07M
Total Debt	16.04M	22.19M	25.30M	28.14M	28.46M	8.74M
Total Liabilities	31.58M	39.35M	41.83M	40.56M	51.78M	21.91M
Stockholders Equity	126.15M	83.28M	116.74M	115.69M	195.90M	307.76M
Cash Flow
Free Cash Flow	21.35M	-62.30M	-66.75M	-85.27M	-102.86M	-52.29M
Operating Cash Flow	21.35M	-62.30M	-66.72M	-85.08M	-100.15M	-52.15M
Investing Cash Flow	-14.25M	16.97M	16.35M	53.37M	130.61M	-281.69M
Financing Cash Flow	341.00K	25.55M	71.93M	177.00K	729.00K	214.94M

Black Diamond Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.79
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDTX, the sentiment is Neutral. The current price of 2.79 is above the 20-day moving average (MA) of 2.61, below the 50-day MA of 3.21, and below the 200-day MA of 2.80, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 49.78 is Neutral, neither overbought nor oversold. The STOCH value of 67.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BDTX.

Black Diamond Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BDTX	59 Neutral	$158.96M	7.69	19.23%	―	―	―
SLS	56 Neutral	$585.44M	-14.33	-84.33%	―	―	59.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DMAC	49 Neutral	$447.87M	-11.99	-64.12%	―	―	-29.73%
VYGR	46 Neutral	$229.63M	-1.90	-46.09%	―	-80.88%	-388.61%
GALT	44 Neutral	$193.44M	-5.07	―	―	―	18.82%
TIL	44 Neutral	$48.76M	-0.63	-50.60%	―	―	1.40%

Black Diamond Therapeutics Corporate Events

Black Diamond Reports Promising Phase 2 Lung Cancer Data

On December 3, 2025, Black Diamond Therapeutics announced preliminary data from its Phase 2 trial of silevertinib in frontline non-small cell lung cancer (NSCLC) patients with non-classical EGFR mutations, showing a 60% objective response rate and 86% CNS response rate. The company plans to initiate a randomized Phase 2 trial of silevertinib in newly diagnosed glioblastoma (GBM) patients in the first half of 2026, with preliminary data expected in 2028, highlighting the potential of silevertinib as a targeted therapy for EGFR-altered GBM.

The most recent analyst rating on (BDTX) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Black Diamond Therapeutics stock, see the BDTX Stock Forecast page.